Development of PROSTVAC immunotherapy in prostate cancer

Parminder - Singh, Sumanta K. Pal, Anitha Alex, Neeraj Agarwal

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

PROSTVAC immunotherapy is a heterologous prime-boost regimen of two different recombinant pox-virus vectors; vaccinia as the primary immunotherapy, followed by boosters employing fowlpox, to provoke immune responses against prostate-specific antigen. Both vectors contain transgenes for prostate-specific antigen and a triad of T-cell costimulatory molecules (TRICOM). In a placebo-controlled Phase II trial of men with minimally symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer, PROSTVAC was well tolerated and associated with a 44% reduction in death. With a novel mechanism of action, and excellent tolerability, PROSTVAC has the potential to dramatically alter the treatment landscape of prostate cancer, not only as a monotherapy, but also in combination with other novel agents, such as immune check point inhibitors and novel androgen receptor blockers. A Phase III trial recently completed accrual.

Original languageEnglish (US)
Pages (from-to)2137-2148
Number of pages12
JournalFuture Oncology
Volume11
Issue number15
DOIs
StatePublished - Aug 1 2015

Fingerprint

Immunotherapy
Prostatic Neoplasms
Prostate-Specific Antigen
Fowlpox
Vaccinia
Castration
Androgen Receptors
Transgenes
Placebos
Viruses
T-Lymphocytes
Drug Therapy
PROSTVAC
Therapeutics

Keywords

  • pox virus immunotherapy
  • prostate cancer
  • PROSTVAC

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Development of PROSTVAC immunotherapy in prostate cancer. / Singh, Parminder -; Pal, Sumanta K.; Alex, Anitha; Agarwal, Neeraj.

In: Future Oncology, Vol. 11, No. 15, 01.08.2015, p. 2137-2148.

Research output: Contribution to journalArticle

Singh, P, Pal, SK, Alex, A & Agarwal, N 2015, 'Development of PROSTVAC immunotherapy in prostate cancer', Future Oncology, vol. 11, no. 15, pp. 2137-2148. https://doi.org/10.2217/fon.15.120
Singh, Parminder - ; Pal, Sumanta K. ; Alex, Anitha ; Agarwal, Neeraj. / Development of PROSTVAC immunotherapy in prostate cancer. In: Future Oncology. 2015 ; Vol. 11, No. 15. pp. 2137-2148.
@article{9b97372326c94042b4cb23d5500ba47c,
title = "Development of PROSTVAC immunotherapy in prostate cancer",
abstract = "PROSTVAC immunotherapy is a heterologous prime-boost regimen of two different recombinant pox-virus vectors; vaccinia as the primary immunotherapy, followed by boosters employing fowlpox, to provoke immune responses against prostate-specific antigen. Both vectors contain transgenes for prostate-specific antigen and a triad of T-cell costimulatory molecules (TRICOM). In a placebo-controlled Phase II trial of men with minimally symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer, PROSTVAC was well tolerated and associated with a 44{\%} reduction in death. With a novel mechanism of action, and excellent tolerability, PROSTVAC has the potential to dramatically alter the treatment landscape of prostate cancer, not only as a monotherapy, but also in combination with other novel agents, such as immune check point inhibitors and novel androgen receptor blockers. A Phase III trial recently completed accrual.",
keywords = "pox virus immunotherapy, prostate cancer, PROSTVAC",
author = "Singh, {Parminder -} and Pal, {Sumanta K.} and Anitha Alex and Neeraj Agarwal",
year = "2015",
month = "8",
day = "1",
doi = "10.2217/fon.15.120",
language = "English (US)",
volume = "11",
pages = "2137--2148",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "15",

}

TY - JOUR

T1 - Development of PROSTVAC immunotherapy in prostate cancer

AU - Singh, Parminder -

AU - Pal, Sumanta K.

AU - Alex, Anitha

AU - Agarwal, Neeraj

PY - 2015/8/1

Y1 - 2015/8/1

N2 - PROSTVAC immunotherapy is a heterologous prime-boost regimen of two different recombinant pox-virus vectors; vaccinia as the primary immunotherapy, followed by boosters employing fowlpox, to provoke immune responses against prostate-specific antigen. Both vectors contain transgenes for prostate-specific antigen and a triad of T-cell costimulatory molecules (TRICOM). In a placebo-controlled Phase II trial of men with minimally symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer, PROSTVAC was well tolerated and associated with a 44% reduction in death. With a novel mechanism of action, and excellent tolerability, PROSTVAC has the potential to dramatically alter the treatment landscape of prostate cancer, not only as a monotherapy, but also in combination with other novel agents, such as immune check point inhibitors and novel androgen receptor blockers. A Phase III trial recently completed accrual.

AB - PROSTVAC immunotherapy is a heterologous prime-boost regimen of two different recombinant pox-virus vectors; vaccinia as the primary immunotherapy, followed by boosters employing fowlpox, to provoke immune responses against prostate-specific antigen. Both vectors contain transgenes for prostate-specific antigen and a triad of T-cell costimulatory molecules (TRICOM). In a placebo-controlled Phase II trial of men with minimally symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer, PROSTVAC was well tolerated and associated with a 44% reduction in death. With a novel mechanism of action, and excellent tolerability, PROSTVAC has the potential to dramatically alter the treatment landscape of prostate cancer, not only as a monotherapy, but also in combination with other novel agents, such as immune check point inhibitors and novel androgen receptor blockers. A Phase III trial recently completed accrual.

KW - pox virus immunotherapy

KW - prostate cancer

KW - PROSTVAC

UR - http://www.scopus.com/inward/record.url?scp=84938488864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938488864&partnerID=8YFLogxK

U2 - 10.2217/fon.15.120

DO - 10.2217/fon.15.120

M3 - Article

C2 - 26235179

AN - SCOPUS:84938488864

VL - 11

SP - 2137

EP - 2148

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 15

ER -